Do analysts prefer BGMS or ATOS?

Atossa Genetics has a consensus price target of $20.33, indicating a potential upside of 733.33%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Atossa Genetics is more favorable than Cyclacel Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is BGMS or ATOS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% Atossa Genetics N/A -84.91% -72.36%

Is RKTO or BGMS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts rate BGMS or LGVN?

Longeveron has a consensus target price of $5.50, indicating a potential upside of 765.73%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Cyclacel Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer BGMS or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BGMS or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer BGMS or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BGMS or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% GT Biopharma N/A N/A -102.03%

Cyclacel Pharmaceuticals (BGMS) Competitors

$0.91 +0.00 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$0.89 -0.02 (-1.81%)

As of 07:50 PM Eastern

Compare

BGMS vs. ATOS, RKTO, LGVN, ZIVO, and GTBP

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? MarketBeat compares Cyclacel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cyclacel Pharmaceuticals include Atossa Genetics (ATOS), Rocket One Inc. Common Stock (RKTO), Longeveron (LGVN), ZIVO Bioscience (ZIVO), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry.

How does Cyclacel Pharmaceuticals compare to Atossa Genetics?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Atossa Genetics (NASDAQ:ATOS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Cyclacel Pharmaceuticals has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.66	-$3M	-$4.54	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Atossa Genetics has a consensus price target of $20.33, indicating a potential upside of 733.33%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Atossa Genetics is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Atossa Genetics	N/A	-84.91%	-72.36%

In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 2 articles in the media. Cyclacel Pharmaceuticals' average media sentiment score of 1.44 beat Atossa Genetics' score of 0.94 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Atossa Genetics	Positive

Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cyclacel Pharmaceuticals beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Rocket One Inc. Common Stock?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cyclacel Pharmaceuticals has higher revenue and earnings than Rocket One Inc. Common Stock. Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Cyclacel Pharmaceuticals	$750K	6.66	-$3M	-$4.54	N/A

Rocket One Inc. Common Stock has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.38, suggesting that its stock price is 138% less volatile than the broader market.

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, suggesting a potential upside of 455.56%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, equities analysts clearly believe Rocket One Inc. Common Stock is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 2 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 1.44 beat Rocket One Inc. Common Stock's score of 0.96 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Rocket One Inc. Common Stock	Positive
Cyclacel Pharmaceuticals	Positive

Summary

Cyclacel Pharmaceuticals beats Rocket One Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Longeveron?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Longeveron (NASDAQ:LGVN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Cyclacel Pharmaceuticals' return on equity of -51.21% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Longeveron	-1,844.49%	-202.41%	-140.67%

Longeveron has a consensus target price of $5.50, indicating a potential upside of 765.73%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Longeveron had 4 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 1.44 beat Longeveron's score of 0.82 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Longeveron	Positive

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.66	-$3M	-$4.54	N/A
Longeveron	$1.20M	16.49	-$22.70M	-$1.13	N/A

Cyclacel Pharmaceuticals has a beta of -0.38, meaning that its share price is 138% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

Summary

Cyclacel Pharmaceuticals and Longeveron tied by winning 8 of the 16 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to ZIVO Bioscience?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.66	-$3M	-$4.54	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

ZIVO Bioscience's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for ZIVO Bioscience. Cyclacel Pharmaceuticals' average media sentiment score of 1.44 beat ZIVO Bioscience's score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
ZIVO Bioscience	Neutral

Summary

Cyclacel Pharmaceuticals beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to GT Biopharma?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and GT Biopharma (NASDAQ:GTBP) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Cyclacel Pharmaceuticals has higher revenue and earnings than GT Biopharma. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.66	-$3M	-$4.54	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of GT Biopharma shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

GT Biopharma's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
GT Biopharma	N/A	N/A	-102.03%

Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than GT Biopharma. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.91 beat Cyclacel Pharmaceuticals' score of 1.44 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
GT Biopharma	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclacel Pharmaceuticals beats GT Biopharma on 7 of the 11 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGMS vs. The Competition

Export

Metric	Cyclacel Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$5.00M	$942.31M	$4.37B	$12.66B
Dividend Yield	N/A	4.84%	30.61%	8.42%
P/E Ratio	-0.20	1.56	23.76	24.38
Price / Sales	6.66	124.34	181.31	93.32
Price / Cash	N/A	20.06	165.47	59.39
Price / Book	0.65	8.58	12.18	6.32
Net Income	-$3M	-$3.40M	$120.20M	$331.55M
7 Day Performance	4.05%	-2.12%	-0.79%	0.08%
1 Month Performance	8.46%	-1.06%	-2.84%	-0.76%
1 Year Performance	N/A	35.43%	11.38%	20.68%

Cyclacel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGMS Cyclacel Pharmaceuticals	1.4219 of 5 stars	$0.91 +0.0%	N/A	N/A	$5.00M	$750K	N/A	14	Analyst Downgrade Short Interest Decrease
ATOS Atossa Genetics	2.5421 of 5 stars	$2.37 +0.4%	$20.33 +757.9%	-83.9%	$20.32M	N/A	N/A	8
RKTO Rocket One Inc. Common Stock	2.0938 of 5 stars	$0.90 -1.4%	$5.00 +457.0%	-44.0%	$20.31M	N/A	N/A	4	Short Interest Decrease Gap Up
LGVN Longeveron	3.0089 of 5 stars	$0.68 +3.8%	$5.50 +714.8%	-56.2%	$20.26M	$1.20M	N/A	20
ZIVO ZIVO Bioscience	N/A	$4.83 +1.7%	N/A	-64.2%	$20.05M	$15.85K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGMS) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. ATOS, RKTO, LGVN, ZIVO, and GTBP

How does Cyclacel Pharmaceuticals compare to Atossa Genetics?

Summary

How does Cyclacel Pharmaceuticals compare to Rocket One Inc. Common Stock?

Summary

How does Cyclacel Pharmaceuticals compare to Longeveron?

Summary

How does Cyclacel Pharmaceuticals compare to ZIVO Bioscience?

Summary

How does Cyclacel Pharmaceuticals compare to GT Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. ATOS, RKTO, LGVN, ZIVO, and GTBP

How does Cyclacel Pharmaceuticals compare to Atossa Genetics?

Which has preferable valuation & earnings, BGMS or ATOS?

Do analysts prefer BGMS or ATOS?

Is BGMS or ATOS more profitable?

Does the media prefer BGMS or ATOS?

Which has more risk & volatility, BGMS or ATOS?

Do institutionals and insiders believe in BGMS or ATOS?

Summary

How does Cyclacel Pharmaceuticals compare to Rocket One Inc. Common Stock?

Do insiders & institutionals believe in RKTO or BGMS?

Which has stronger earnings and valuation, RKTO or BGMS?

Which has more volatility and risk, RKTO or BGMS?

Is RKTO or BGMS more profitable?

Do analysts rate RKTO or BGMS?

Does the media refer more to RKTO or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Longeveron?

Is BGMS or LGVN more profitable?

Do analysts rate BGMS or LGVN?

Do insiders & institutionals have more ownership in BGMS or LGVN?

Does the media refer more to BGMS or LGVN?

Which has preferable valuation and earnings, BGMS or LGVN?

Which has more volatility and risk, BGMS or LGVN?

Summary

How does Cyclacel Pharmaceuticals compare to ZIVO Bioscience?

Which has more volatility & risk, BGMS or ZIVO?

Do institutionals and insiders have more ownership in BGMS or ZIVO?

Which has better earnings & valuation, BGMS or ZIVO?

Is BGMS or ZIVO more profitable?

Do analysts prefer BGMS or ZIVO?

Does the media refer more to BGMS or ZIVO?

Summary

How does Cyclacel Pharmaceuticals compare to GT Biopharma?

Which has stronger earnings and valuation, BGMS or GTBP?

Do insiders and institutionals believe in BGMS or GTBP?

Is BGMS or GTBP more profitable?

Which has more risk and volatility, BGMS or GTBP?

Does the media refer more to BGMS or GTBP?

Do analysts prefer BGMS or GTBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools